AN2 Therapeutics, Inc. (ANTX) has a consensus analyst rating of Buy, based on 8 analysts covering the stock. Of those, 5 recommend buying, 3 recommend holding, and 0 recommend selling.
The analyst consensus price target for ANTX is $7.75, representing a +160.1% upside from the current price of $2.98. Price targets range from a low of $2.00 to a high of $22.00.
